|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fluconazole,a review of pharcodynamic and pharmacokinetic properties,and therapeutic potential in superficial and systemic mycoses显示文摘 | GRANT S M CLISSOLD S P | 1990 | Drugs1990，39，： | 1 |
| 2 | Paroxetine:a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potentialin depressive illness显示文摘 | Dechant KL Clissold SP | 1991 | Drugs1991，4，： | 1 |
| 3 | Paroxetine:a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive ill-ness显示文摘 | Clissold SP | 1991 | Drugs1991，4，： | 1 |
| 4 | Nicardipine显示文摘 | Sorkin EM Clissold SP | 1987 | Drugs1987，33，： | 1 |
| 5 | A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses显示文摘 | Grant SM Clissold SP Fluconazole | 1990 | Drugs1990，39，： | 1 |
| 6 | Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain:the '5E' study 显示文摘 | Arroyo R Vila C Clissold S | 2011 | Expert Rev Pharmacoecon Outcomes Res2011，11，2： | 1 |
| 7 | Naproxen-a resppraisal of its pharmacology,and therapeutic use in rheumatic diseases and stetas显示文摘 | Todd P A Clissold S P | | 0，，01： | 1 |
| 8 | Slits and roundabouts in cancer,tumour angiogenesis and endothelial cell migration显示文摘 | Legg JA Herbert JM Clissold P | | 0，，： | 1 |
| 9 | Calcipotriol: a review of its phar- macological properties and therapeutic use in psoriasis vulgaris 显示文摘 | Murdoch D Clissold SP | 1992 | Drugs1992，43，3： | 1 |
| 10 | Metoprolol an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders 显示文摘 | Benfield P Clissold SP Brogden RN | 1986 | Drugs1986，31，5： | 1 |
| 11 | Clafithromycin: A review of its antimierobial activity, pharmaceutic properties and therapeutic potential 显示文摘 | PETER D H CLISSOLD S P | 1992 | Drugs1992，44，1： | 1 |
| 12 | Paroxetine:A reriew of its pharmacodynamic and phamacokinetic properties and therapeutic potential in depressive illness显示文摘 | Kerry L Clissold SP | 1991 | Drugs1991，41，2： | 1 |
| 13 | Slits and Round- abouts in cancer, tumour angiogenesis and endothelial cell migration显示文摘 | Legg JA Herbert JM Clissold P | 2008 | Angiogenesis2008，11，1： | 1 |
| 14 | Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments. | Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis | 2022 | Stroke & Vascular Neurology2022，7，2： | 1 |
| 15 | Nifedipine:a review of its pharmacodynamic and pharmacokinetic properties,and therapeutic efficacy,in ischemic heart disease,hypertension and related cardiovascular disorders显示文摘 | Sorkin EM Clissold SP Brogden RN | 1985 | Drugs1985，30，3： | 1 |
| 16 | Nicardipine:a review of its pharmacodynamic and pharmacokinetic properties,and therapeutic efficacy,in the treatment of angina pectoris,hypertension and related cardiovascular disorders显示文摘 | Sorkin EM Clissold SP | 1987 | Drugs1987，33，4： | 1 |
| 17 | A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states显示文摘 | TODD P A CLISSOLD S P | | 0，，01： | 1 |
| 18 | Nicardipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders 显示文摘 | Clissold SP | 1987 | Drugs1987，33，4： | 1 |
| 19 | The Biomechanics of Chewing and Plant Fracture: Mechanisms and Implications显示文摘 | Fiona J. Clissold | 2008 | Advances in Insect Physiology2008，，： | 1 |
| 20 | Flucomazole, A review of its phamacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses显示文摘 | Grant SM Clissold SP | 1990 | Drugs1990，39，60： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员